Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Thrombocytopenia; This is a spontaneous report from a contactable physician. This is the second of two reports. The first report is a report downloaded from a regulatory authority-WEB. The regulatory authority report number is SE-MPA-2021-026203, other case identifier is SE-VISMA-1618071388697. A 62-year-old female patient received the first dose of BNT162B2 (COMIRNATY, batch/lot number: unknown), via an unspecified route of administration on 2021 (at an unspecified age) at single dose for COVID-19 immunisation. Medical history included pancreatic cancer metastatic (liver and spleen) detected in Feb2021 and ongoing, ongoing type 2 diabetes mellitus, ongoing hypertension, ongoing obesity, ongoing multiple sclerosis, skin disease with blisters on the skin. The patient did not have any treatment for the multiple sclerosis and she had impaired liver function so she had not started any cancer treatment. Concomitant medications included furosemide (FURIX), oxycodone, enalapril, diclofenac sodium (VOLTAREN), metformin, insulin glargine (TOUJEO), omeprazole, insulin lispro (INSULIN LISPRO SANOFI). The patient experienced thrombocytopenia on 2021. The reporter stated that the thrombocytopenia started 8 days after the first dose of BNT162B2. The outcome of the event was fatal. The patient died on an unspecified date in 2021. It was unknown if an autopsy was performed. Report was assessed as serious due to death. No follow-up attempts possible. No further information expected. Information on lot and batch numbers cannot be obtained.; Sender''s Comments: Linked Report(s) : SE-PFIZER INC-2021414361 the same patient/reporter, different event/dose; Reported Cause(s) of Death: Thrombocytopenia
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166